

Chapter 1

Recent Progress in Engineering Human-Associated Microbiomes

Stephanie J. Yaung, George M. Church, and Harris H. Wang

Abstract

Recent progress in molecular biology and genetics opens up the possibility of engineering a variety of biological systems, from single-cellular to multicellular organisms. The consortia of microbes that reside on the human body, the human-associated microbiota, are particularly interesting as targets for forward engineering and manipulation due to their relevance in health and disease. New technologies in analysis and perturbation of the human microbiota will lead to better diagnostic and therapeutic strategies against diseases of microbial origin or pathogenesis. Here, we discuss recent advances that are bringing us closer to realizing the true potential of an engineered human-associated microbial community.

Key words Microbiome, Microbiota, Synthetic biology, Systems biology, Microbial engineering, Functional metagenomics, Host–microbe interactions

1 Introduction

Of the 100 trillion cells in the human body, 90 % are microbes that naturally inhabit various body sites, including the gastrointestinal tract, nasal and oral cavities, urogenital area, and skin [1]. An individual's colon is home to 10^{11} – 10^{12} microbial cells/mL, the greatest density compared to any other microbial habitat characterized to date [2]. Many studies, such as the Human Microbiome Project and MetaHIT, have probed the vast effects of microbiota on human health and disease [1, 3–5]. In addition to metagenomic sequencing [6], traditional methods of studying cells in isolation are important for elucidating molecular bases of microbial activity. However, cells do not exist in single-species cultures in nature. In fact, some species are only culturable in the presence of other microorganisms [7]. This interdependence for survival amongst microbial species in a community attests to the importance of intercellular interactions, both microbe–microbe and host–microbe. Despite the fact that the human microbiota is composed of many individual microbes, these individuals work in concert to




Fig. 1 Engineering human-associated microbiota requires detailed understanding of processes that govern the natural propagation and retention of microbes in the host as well as environmental and adaptive pressures that drive the evolution of cells and communities

perform tasks that rival in complexity to those of more sophisticated multicellular systems. Thus, the human-associated microbiome presents a ripe opportunity for forward engineering to potentially improve human health (Fig. 1). Here, we review recent advances in this area and outline potential avenues for future endeavors.

2 Microbiota, Host, and Disease

Contrary to traditional views, microbes are social organisms that engage with the environment and other organisms in specific ways. Microbes participate in intercellular communication through contact-dependent signaling [8], quorum sensing [9], metabolic cooperation or competition [5], spatiotemporal organization [10], and horizontal gene transfer (HGT) [11]. Human-associated microbes produce by-products that serve as substrates utilized by other resident bacteria [12–14]. For instance, accumulated hydrogen gas from bacterial sugar fermentation is removed by acetogenic, methanogenic, and sulfate-reducing gut bacteria [15]. In contrast to cross-feeding relationships, microbes under stress can release bacteriocins to suppress the growth of competitors [16–18]. If microbes are members of a biofilm community, they benefit from physical protection from the environment, access to nutrients trapped and distributed through channels in the biofilm, development of syntrophic relationships with other members, and the ability to share and acquire genetic traits [19, 20]. Microbial populations also

Gut microbiota composition during human development




Fig. 2 Composition of the human gut microbiome during development with respect to microbial diversity and population stability. Data compiled from recent studies from the literature: (a) Hong 2010 [169]; (b) Saulnier 2011 [170]; (c) Claesson 2011 [171]; (d) Yatsunenکو 2012 [172]; (e) Spor 2011 [173]

genetically diversify to insure against possible unstable environmental conditions [21, 22]. Moreover, multispecies communities harbor a dynamic gene pool consisting of mobile genetic elements, such as transposons, plasmids, and bacteriophages, which serve as a source of HGT to share beneficial functions with neighbors to preserve community stability [23–26]. Densely populated communities such as the human gut are active sites for gene transfer and reservoirs for antibiotic resistance genes [11, 27–29].

Beyond microbe–microbe interactions, the microbiota coevolves with the host as it develops, driving microbial adaptation [30–33]. Core functions of microbiota benefit the host, such as extraction of otherwise inaccessible nutrients, immune system development, and protection against pathogen colonization [2, 34–37]. Gut microbes are critical in intestinal angiogenesis, epithelial cell maturation, and immunological homeostasis [37–40]. For example, the commensal *Bacteroides fragilis* produces polysaccharide A, which converts host CD4⁺ T cells into Foxp3⁺ T_{reg} cells, producing interleukin-10 (IL-10) and inducing mucosal tolerance [41]. Host diet, inflammatory responses, and aging also affect microbial community composition and function [42–45] (Fig. 2). Indeed, aberrations in host genetics, immunology, and diet can lead to

microbiota-associated human diseases. Diet-induced obesity in mice from a high-fat diet is characterized by enhanced energy harvest and an increased *Firmicutes*-to-*Bacteroidetes* ratio [46, 47]. Furthermore, disruptions in the homeostasis between gut microbial antigens and host immunity can invoke allergy and autoimmunity, as in type 1 diabetes and multiple sclerosis [48–50]. It is thought that inflammatory bowel disease (IBD) results from inappropriate immune responses to intestinal bacteria; genes identified in genome-wide association studies highlight the role of a host imbalance between pro-inflammatory and regulatory states [48, 51].

While the host selects for microbial communities that harvest nutrients and prime the immune system, irregular microbiota composition may cause disease (Fig. 3), including IBD [52–54],




Fig. 3 Changes in the composition of human microbiota during disease states compared to healthy states. Data compiled from recent studies from the literature: (a) De Filippo 2010 [174]; (b) Peterson 2008 [175]; (c) Larsen 2010 [176]; (d) Kong 2012 [177]; (e) Gao 2012 [178]; (f) Keijsers 2008 [179]; (g) Yang 2012 [180]

lactose intolerance [55, 56], obesity [57, 58], type I diabetes [59], arthritis [60], myocardial infarction severity [61], and opportunistic infections by pathogens such as *Clostridium difficile* and HIV [62–65]. Microbial gut metabolism links host diet not only to body composition and obesity [66] but also to chronic inflammatory states, such as IBD, type 2 diabetes, and cardiovascular disease [67–69]. Intestinal microbes are also important in off-target drug metabolism, rendering digoxin, acetaminophen, and irinotecan less effective or even toxic [70–72]. In the case of irinotecan, a chemotherapeutic used mainly for colon cancer, the drug is metabolized by β -glucuronidases of commensal gut bacteria into a toxic form that damages the intestinal lining and causes severe diarrhea. In the oral cavity, ecological shifts in dental plaque microbiota lead to caries (cavities), gingivitis, and periodontitis [73]. Dental caries arise from acidic environments generated by acidogenic (acid-forming) and aciduric (acid-tolerant) bacteria, which metabolize sugar from the host diet. Translocation of oral bacteria into other tissues results in infections, and cytokines from inflamed gums released into the bloodstream stimulate systemic inflammation. Oral bacteria have been implicated in respiratory [74, 75] and cardiovascular diseases [76–78], though mechanisms remain unclear.

3 Enabling Tools for Engineering the Microbiota

The human-associated microbial community presents a vast reservoir of nonmammalian genetic information that encodes for a variety of functions essential to the mammalian host [79]. Next-generation sequencing technologies have enabled us for the first time to systematically probe the genetic composition of these trillions of microbes that reside on the human body [1]. The ongoing effort by the Human Microbiome Project and MetaHIT to catalog dominant microbial strains from different body sites has generated useful reference genomes for many of the representative species [80]. Metagenomic shot-gun sequencing approaches of whole microbial communities, such as those found in the gut, have yielded near-complete gene catalogs that describe abundance and diversity of genes that contribute to maintenance and metabolism of the microbiota [6].

In order to determine functional relationships between human-associated microbes and their concerted effect in the mammalian host, we rely on functional perturbation of the microbial community. These investigative avenues include genome-scale perturbation assays, specified community reconstitutions, and directed engineering through synthetic biology (Fig. 4). Each approach provides us with a unique angle to attack an otherwise daunting




Fig. 4 General approaches to engineer the human microbiome through design, quantitative modeling, genome-scale perturbation, and analysis in *in vitro* and *in vivo* models, with the ultimate goal of producing demand-meeting applications to improve sensing, prevention, and treatment of diseases

challenge of de-convolving a highly intertwined set of microbial interactions in a very heterogeneous environment and a difficult-to-manipulate human host. Advances in both *in vitro* and *in vivo* host models have thus also facilitated research endeavors in this area, which we discuss in the following sections.

3.1 Challenges of Building New Genetic System

Approaches to study the function of human-associated microbes by genetic manipulation rely on several fundamental capabilities, which are often the largest practical barriers to manipulate microbes genetically. First, individual microbes need to be isolated and cultured in the laboratory. Because microbes have a myriad of physiologies and require different nutritional supplement for growth, different media compositions and growth conditions need to be laboriously tested by trial and error to isolate and culture each microbe. These microbial culturing techniques date back to the times of Louis Pasteur and are still the dominant approach today. More recent microbial cultivation techniques use microfluidics and droplet technologies to enable the discovery of synergistic interactions between natural microbes that allow otherwise “unculturable” organisms to be grown in laboratory conditions [7, 81, 82].

Upon successful microbial cultivation, the next limiting step of microbial genetic manipulation is the transformation of foreign DNA into cells. The passage of foreign DNA (e.g., plasmids, recombinant fragments) into the cell requires overcoming the physical barriers presented by the cell wall or membrane. This task is accomplished in nature through processes such as transduction by phage, conjugation and mating, or natural competency and DNA uptake [83, 84]. Numerous laboratory techniques have been developed for microbial transformation including electroporation [85], biolistics [86], sonication [87], and chemical or heat disruption [88]. Electroporation, the most common of the laboratory transformation techniques, relies on high-voltage electrocution of the bacterial sample that is thought to transiently induce pores on the cell membrane (hence “electroporation”) that then enable extracellular DNA to diffuse into the cell. Various protocols for electroporation of human-associated microbes have been described and are good starting points for developing genetic systems in these microbes [89, 90].

Upon transformation of DNA into the cell, the DNA needs to either stably propagate intracellularly or integrate into the microbial host genome through recombination or other integration strategies. Inside the cell, stable propagation of episomal DNA such as plasmids requires DNA replication machinery that is compatible with the foreign DNA [83]. Additionally, cells often use methylation and DNA modification and restriction systems to discern foreign versus host DNA through a primitive defensive mechanism that fights against viruses or other invading genetic elements. Nonetheless, these promiscuous genetic elements can often be used as a way to integrate foreign DNA into the chromosome and are often used for large-scale functional genomics [91].

Taking all these parameters into consideration, we have summarized (Fig. 5) the current genetic tractability of human-associated microbes with respect to culturability, availability of full genome sequences, transfection methods, and expression and manipulation systems. Expansion of these basic genetic tools is crucial for future functional studies of human microbiota.




Fig. 5 Genetic tractability of abundant or relevant human-associated microbial genera, evaluated by the availability of means to introduce genetic material (e.g., transformation, conjugation, or transduction), vectors, expression systems, completed genomic sequences, and culturing methods. Circles of increasing sizes indicate greater genetic tractability. Protocols and demonstrated methods for genetic manipulation are listed as follows: (a) *Clostridium*: Phillips-Jones 1995, Jennert 2000, Young 1999, Bouillaut 2011 [181–184]; (b) *Ruminococcus*: Cocconcelli 1992 [185]; (c) *Lactobacillus*: van Pijkeren 2012, Ljungh 2009, Damelin 2010, Sorvig 2005, Thompson 1996, Lizier 2010 [107, 186–190]; (d) *Enterococcus*: Shepard 1995 [191]; (e) *Lactococcus*: Holo 1995, van Pijkeren 2012 [107, 192]; (f) *Streptococcus*: McLaughlin 1995, Biswas 2008 [193, 194]; (g) *Staphylococcus*: Lee 1995 [195]; (h) *Listeria*: Alexander 1990 [196]; (i) *Treponema*: Kuramitsu 2005 [197]; (j) *Borrelia*: Hyde 2011, Rosa 1999 [198, 199]; (k) *Bifidobacterium*: Mayo 2010 [200];

3.2 Genome-Scale Perturbations

Genome-scale perturbations are a class of genetic approaches that disrupt or perturb the expression of functional genes that contribute to relevant phenotypes by individual microbes. To dissect the function of different genes in the cell, we have relied heavily on the use of transposons, which are selfish genetic elements that can splice into and out of different locations of chromosomal DNA, thereby disrupting the coding sequence [92]. This classical approach, known as transposon mutagenesis, has allowed us to isolate many genetic mutants whose disrupted genes give rise to interesting phenotypes that reflect the importance of those genes to its physiology. Next-generation DNA sequencing has now enabled multiplexed genotyping of pools of transposon mutants by using molecular barcodes that then can be applied to measure the effect of genome-scale perturbations in different environmental conditions. For example, techniques such as insertion sequencing (INSeq) [93] utilize the inverted repeat recognition of the Himar transposase, which is one nucleotide change away from the restriction site for type II restriction enzyme MmeI, to generate paired 16–17 bp flanking genomic sequences around the transposon that can be sequenced in pools. Thus, the defined insertion location of every transposon in the library can be determined. By sequencing this pooled mutant library pre- and posttreatment with any number of environmental perturbations, one can probe the effects of different gene disruptions on the physiology of the cell in a multiplexed fashion. Similar techniques using other transposon systems such as transposon sequencing (Tn-seq) [94], high-throughput insertion tracking by deep sequencing (HITS) [95], and transposon-directed insertion-site sequencing (TraDIS) [96] have also been developed.

In addition to transposon-based systems, shotgun expression libraries have been useful in discovering functional DNA elements in genomic or metagenomic DNA. Shotgun expression libraries rely on physical shearing or restriction digestion of a donor DNA source into smaller DNA fragments that are then cloned into a gene expression vector and transformed into a host strain for functional analysis. A library of metagenomic DNA samples can for example be extracted from an environment and cloned into plasmids that are then expressed in *E. coli*. Selection and sequencing of the *E. coli* population for heterologous DNA that enable new function lead to discovery of novel gene elements that perform a particular

Fig. 5 (continued) (l) Actinomyces: Yeung 1994 [201]; (m) Mycobacterium: Parish 2009, Sassetti 2001 [202, 203]; (n) Propionibacterium: Luijk 2002 [204]; (o) Chlamydia: Binet 2009 [205]; (p) Porphyromonas: Belanger 2007 [206]; (q) Prevotella: Flint 2000, Salyers 1992 [207, 208]; (r) Bacteroides: Salyers 1999, Smith 1995, Bacic 2008 [209–211]; (s) Fusobacterium: Haake 2006 [212]; (t) Helicobacter: Taylor 1992, Segal 1995 [213, 214]; (u) Campylobacter: Taylor 1992 [214]; (v) Rickettsia: Rachek 2000 [215]; (w) Brucella: McQuiston 1995 [216]; (x) Bordetella: Scarlato 1996 [217]; (y) Neisseria: O’Dwyer 2005, Bogdon 2002, Genco 1984 [218–220]; (z) Pseudomonas: Dennis 1995 [221]

activity. This approach can easily identify activities such as antibiotic resistance [97] but have yielded less success with other functions.

Towards forward engineering of human-associated microbes, new genome engineering tools such as trackable multiplex recombinering (TRMR) [98, 99] and multiplex automated genome engineering (MAGE) enable efficient, site-specific modification of the genome [100–103]. TRMR combines double-stranded homologous recombination [104] and molecular barcodes synthesized from DNA microarrays to generate populations of mutants that are trackable by microarray or sequencing. MAGE relies on introduction of pools of single-stranded oligonucleotides that target defined locations of the genome to introduce regulatory mutations [102] or coding modifications [105]. These and other recombinering technologies are now being developed for a variety of other organisms including gram-negative bacteria [106], lactic acid bacteria [107], *Pseudomonas syringae* [108], and *Mycobacterium tuberculosis* [109], and are likely to be very useful for engineering human-associated microbes.

3.3 Reconstituted Communities

The community of microbes that make up the human microbiome can be considered a “pseudo-organ” of its own. These microbes interact with one another and the mammalian host in potentially highly complex ways that may be difficult to decipher even with tractable genetic systems [110]. A direct approach to study these interactions is to build reconstituted communities of microbes derived from monoculture isolates in defined combinations. This de novo reconstitution approach to build synthetic communities has significant advantages over attempts to deconvolute natural communities. Reconstituted synthetic consortium presents a tractable level of complexity in terms of number of interacting microbial species that can be tracked by sequencing and predicted with quantitative models. In one such study, researchers inoculated germ-free mice with ten representative strains of the human microbiota [111]. The mice were then fed with defined diets of macronutrients consisting of proteins, fats, polysaccharides, and sugars. By tracking the abundance of the ten-member microbial consortium using high-throughput sequencing, the researchers could predict over 60 % of the variation in species abundance as a result of diet perturbations. This avenue of investigation presents a viable approach to study the human microbiome and ways to analyze synthetically engineered microbiota.

Engineered microbes have been utilized to reconstitute synthetic communities to investigate the role of metabolic exchange. One such important metabolic exchange is that of amino acids, as they are the essential constituents of proteins. Various syntrophic cross-feeding communities have been described using auxotrophic *E. coli* and yeast strains that require different amino acid supplementation for growth [112–114]. In these syntrophic

systems, metabolites that are exchanged across different biosynthetic pathways promote more syntrophic growth than those that are exchanged along the same pathway, which also relates to the cost of biosynthesis of the amino acid metabolites. Amino acid exchange is likely a large player in driving metabolism of microbial communities as a substantial fraction of all microbes are missing biosynthesis of various metabolites and thus require growth on more rich and complex substrates that are found in the gut [115].

3.4 Microbial Engineering Through Synthetic Biology

New approaches are now utilizing synthetic biology to engineer human-associated microbiota to improve health and metabolism as well as to monitor and fight diseases. These efforts focus on developing genetic circuits that actuate in an engineered host cell such as *E. coli* that can sense and respond to changes to its environment and in the presence of particular pathogens. For example, to detect the human opportunistic pathogen *Pseudomonas aeruginosa*, which often causes chronic cystic fibrosis infections and colonizes the gastrointestinal tract, *E. coli* was engineered to detect the small diffusible molecule that is excreted by *P. aeruginosa* through the quorum sensing pathway [116]. An engineered synthetic circuit was placed in nonpathogenic *E. coli*, which when placed in the presence of high-density *P. aeruginosa* triggered a self-lysis program that released a narrow-spectrum bacteriocin that specifically killed the *P. aeruginosa* strain. Similar strategies have also been demonstrated to detect and respond to *Vibrio cholera* infection using engineered *E. coli* that sense autoinducer-1 (AI1) molecules from *V. cholera* quorum sensing pathway [117]. These strategies appear to yield improved survival rates against microbial pathogenesis in murine models [117]. Quorum sensing systems, which normally help microbes detect local cell density, have been further enhanced to improve robustness and performance to enable coupled short-range and long-range feedback circuits that enable microbial communication across large distances in an engineered community.

Other microbes have been successfully engineered to perform specific functions on human-associated surfaces such as the mucosal layer of the gut epithelium. Numerous diseases that occur along the intestinal tract are targets of such engineered approaches. For example, the probiotic strain *Lactococcus lactis* has been engineered to secrete recombinant human IL-10 in the gastrointestinal tract to reduce colitis [118, 119]. Other future applications of engineered probiotics include enhancing catabolism of nutrients (e.g., lactose and gluten), modulation of the immune system, and removal of pathogens by selective toxin release [116].

3.5 In Vitro Host Models

To probe and engineer the human-associated microbial community, various in vitro models have been developed, ranging from traditional batch culturing in chemostats to microfluidic systems that incorporate host cells. Single-vessel chemostats inoculated

with fecal samples from healthy individuals have helped identify HGT [120] and selective bacterial colonization on different carbohydrate substrates [121, 122]. A multichamber continuous culture system mimicking spatial, nutritional, and pH properties of different GI tract regions can be used to investigate stabilization dynamics [123–125]. Similarly, the constant-depth film fermenter resembles oral biofilm [126] and has enabled studies on biofilm formation, antibiotic resistance [126], and HGT in a multispecies oral community [127, 128]. To incorporate mammalian cells in studying host–microbial interactions, organ-on-a-chip microfluidic devices have been recently used. In one version of such a system, a gut-on-a-chip device, the microfluidic channel is coated with extracellular matrix and lined by human intestinal epithelial (Caco-2) cells. This system mimics intestinal flow and peristaltic motion, recapitulates columnar epithelium polarization and intestinal villi formation, and supports the growth of commensal *Lactobacillus rhamnosus* GG [129]. These microdevices offer an opportunity to investigate host–microbiota interactions in a well-controlled manner and in physiologically relevant conditions.

Inoculating with native microbiota samples provides a method to overcome the un-cultivability of many microbes as well as to study collective activity and discover novel functions without a priori knowledge of community composition. However, starting with a predefined microbial community allows a controlled setting better suited for testing engineered systems. In one study analyzing the dynamics of a community representing the four main gut phyla in a chemostat, the authors propose that intrinsic microbial interactions, rather than host selective pressure, play a role in the observed colonization pattern, which was similar to what has been documented in the human gut [130]. Similar models have been developed for oral microbiota studies. The use of predefined oral microbial inocula has helped elucidate metabolic cooperation in batch culture [12] and community development in saliva-conditioned flow cells [131].

3.6 In Vivo Host Models

In order to move into in vivo animal models that more closely represent the physiology of the human host environment, researchers have extensively utilized murine models including germ-free, gnotobiotic, and conventionally raised mice. Gnotobiotic animals are born in aseptic conditions and reared in a sterile environment where they are exposed only to known microbial species; technically, germ-free mice are a type of gnotobiotic mice that have not been exposed to any microbes. Similar to in vitro systems, mice can be inoculated with either a natural microbiota sample or a predefined microbial community. Fecal samples, as well as oral swab and saliva samples, can then be collected from gnotobiotic mice for biochemical analysis and species quantification of gut and oral cavity microbiota. In vivo models have been used to study the

transmission of antibiotic resistance in the mouse gut [132, 133] and colonization resistance in the oral cavity [134]. Furthermore, the choice of the inoculum donor offers opportunities to compare different host selection pressures and microbial community responses. Microbiota can be transplanted from conventionally raised to germ-free animals of not only the same species but also interspecies, as in human microbiota into mouse, called humanized gnotobiotic mice [134]. In one study, transplants from zebrafish gut microbiota into germ-free mice and mouse gut microbiota into germ-free zebrafish revealed that the resulting community conformed to the native host composition, demonstrating host selection [135].

Altering host diet, environment, or genetic background can also enable studies in host–microbiota interactions. One method to gain insight into the role of microbial communities in disease is to utilize mice with recapitulated pathologies. For example, IL-10^{-/-}, ob^{-/-}, apoE^{-/-}, and TLR2^{-/-} or TLR5^{-/-} mice are models for colitis, obesity, hypercholesterolemia, and metabolic syndrome, respectively [46, 136–139]. To generate antigen- or pathogen-specific phenotypes, mice can be infected with *Salmonella typhimurium* to study colitis [140] or *Citrobacter rodentium* as a model for attaching and effacing pathogens, such as enterohemorrhagic *E. coli* [141, 142]. Furthermore, murine models with chemically induced inflammation can be tools to study chronic mucosal inflammation; dextran sodium sulfate (DSS) can induce ulcerative colitis, and trinitrobenzene sulfonic acid (TNBS) can stimulate Crohn’s disease [143]. To investigate oral microbiota, there are periodontal disease [144] and oral infection models [145, 146]; gnotobiotic rodents can also be fed a high-sucrose cariogenic diet to promote plaque formation.

Germ-free mice inoculated with defined microbes are informative models for analyzing microbial colonization and metabolic adaptation [147]. For example, resident bacteria and probiotic strains adapt their substrate utilization: in the presence of *Bifidobacterium longum*, *Bifidobacterium animalis*, or *Lactobacillus casei*, *Bacteroides thetaiotaomicron* diversified its carbohydrate utilization by shifting metabolism from mucosal glycans to dietary plant polysaccharides [148]. Furthermore, the effect of different diets on microbial community composition can be studied, as in gnotobiotic mice inoculated with ten sequenced gut bacterial species and fed with various levels of casein, cornstarch, sucrose, and corn oil to represent protein, polysaccharide, sugar, and fat content in the diet, respectively [111].

3.7 Computational Frameworks for Human Microbiomics

Over the past several decades, a large number of theoretical and quantitative models have been developed to describe the cell and its behavior. Constrain-based models are used to describe metabolism of individual cells using stoichiometric representation

of metabolic reactions and optimization constraints [149]. Approaches such as flux balance analysis (FBA) enable the analysis of metabolism under steady-state assumptions by linear optimization solution methods. These methods are now being scaled to ecosystems of cells. Recent developments using multi-level objective optimization [150] and dynamic systems [151] enable the modeling of synthetic ecosystems of three or more members. Using metagenomic data of the gut microbiome, Greenblum et al. generated a community-level metabolic reconstruction network of the microbiota and discovered topological variations that are associated with obesity and IBD, giving rise to low diversity and differences in community composition [152]. For models that account for systems dynamics, population abundance and metabolite concentrations can be solved independently through different FBA models that are iterated at each time step. This approach called dynamic multi-species metabolic modeling (DMMM) can capture scenarios of resource competition, leading to the identification of limiting metabolites [153]. Other complementary models include elementary mode analysis (EMA) [154] that enables quantitative analysis of microbial ecosystems in a multicellular fashion.

4 Perspectives

Reframing the microbiota community as a core set of genes, not a core set of species, opens a new front to the microbiome engineering design space. In a metagenomic study of 154 individuals, no single-gut bacterial phylotype was detected at an abundant frequency amongst all the samples, a finding that is consistent with the idea that the core human gut microbiome may not be best defined by prominent species but by abundantly shared genes and functions [155]. We propose that manipulation at the gene, genome, and ultimately metagenome level offers the ability for precise multicellular engineering of desirable traits in human-associated microbiota. Besides controlled perturbations of the microbiome to advance our understanding of host–microbiota interactions, metagenome-scale tools enable novel developments in diagnostics and therapeutics.

From biosensors on the skin to reporters in the gut, there are several opportunities in monitoring the health and disease status of the human host, such as sensing nutritional deficiencies, immune imbalances, environmental toxins, or invading pathogens. Prophylactic and therapeutic avenues for human microbiome engineering include modifying community composition, tuning metabolic activity, mediating microbe–microbe relationships, and modulating host–microbe interactions. Two current microbiota-associated treatments

have shown clinical efficacy: (1) fecal transplants for recurrent *Clostridium difficile* infection [156] and (2) probiotics for pouchitis, which is inflammation of the ileal pouch that is created after surgical removal of the colon in ulcerative colitis patients [157–159]. The main challenge is transmission of undesirable agents from donor feces to the recipient gut in fecal transplants and native colonization resistance that would impair infiltration and growth of new species in probiotics [160, 161]. Nevertheless, these successful approaches demonstrate the potential benefits of leveraging natural microorganisms and entire microbial communities.

In fact, coupling organismal and functional gene-level approaches would be a powerful way to engineer the native microbiota. Microbiome engineering enables multiscale system design for the synthesis of nutrients and vitamins, enhanced digestion of gluten and lactose, decreased acidity of the oral cavity, targeted elimination of multidrug-resistant pathogens, and microbial modulation of the host immune system. As vehicles for drug delivery, commensal bacteria designed to secrete heterologous genes have been explored for treating cancer [162–164], diabetes [165], HIV [166], and IBD [118]. For example, IL-10 has immunomodulatory effects in IBD but requires localized delivery at the intestinal lining to avoid the toxic side effects and low efficacy of systemic IL-10 injection. Ingestion of modified *Lactococcus lactis* that secrete recombinant IL-10 is safe and effective in animal models and has been promising in human clinical trials for IBD [119, 167].

Finally, besides addressing clinical safety and efficacy criteria for FDA regulatory approval [168], overall safety precautions are critical considerations to minimize unintentional risks in releasing genetically modified material into the natural environment. Rational design, such as creating auxotrophic microbes [119], for robust stability, non-pathogenicity, and containment of recombinant genetic systems will be essential in microbiome engineering.

Acknowledgements

H.H.W. acknowledges the generous support from the National Institutes of Health Director's Early Independence Award (grant 1DP5OD009172-01). S.J.Y. acknowledges support from the National Science Foundation Graduate Research Fellowship and the MIT Neurometrix Presidential Graduate Fellowship. G.M.C. acknowledges support from the Department of Energy Genomes to Life Center (Grant DE-FG02-02ER63445).

References

1. Huttenhower C, Gevers D, Knight R et al (2012) Structure, function and diversity of the healthy human microbiome. *Nature* 486:207–214
2. Ley RE, Peterson DA, Gordon JI (2006) Ecological and evolutionary forces shaping microbial diversity in the human intestine. *Cell* 124:837–848
3. Turnbaugh PJ, Ley RE, Hamady M et al (2007) The human microbiome project. *Nature* 449:804–810
4. Nicholson JK, Holmes E, Wilson ID (2005) Gut microorganisms, mammalian metabolism and personalized health care. *Nat Rev Microbiol* 3:431–438
5. Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. *Nature* 449:811–818
6. Qin J, Li R, Raes J et al (2010) A human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 464:59–65
7. Kaeberlein T, Lewis K, Epstein SS (2002) Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. *Science* 296:1127–1129
8. Hayes CS, Aoki SK, Low DA (2010) Bacterial contact-dependent delivery systems. *Annu Rev Genet* 44:71–90
9. Bassler BL, Losick R (2006) Bacterially speaking. *Cell* 125:237–246
10. Walker AW, Duncan SH, Harmsen HJ et al (2008) The species composition of the human intestinal microbiota differs between particle-associated and liquid phase communities. *Environ Microbiol* 10:3275–3283
11. Smillie CS, Smith MB, Friedman J et al (2011) Ecology drives a global network of gene exchange connecting the human microbiome. *Nature* 480:241–244
12. Bradshaw DJ, Homer KA, Marsh PD et al (1994) Metabolic cooperation in oral microbial communities during growth on mucin. *Microbiology* 140:3407–3412
13. Falony G, Vlachou A, Verbrugghe K et al (2006) Cross-feeding between *Bifido-bacterium longum* BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose. *Appl Environ Microbiol* 72:7835–7841
14. Salazar N, Gueimonde M, Hernández-Barranco AM et al (2008) Exopolysaccharides produced by intestinal *Bifidobacterium* strains act as fermentable substrates for human intestinal bacteria. *Appl Environ Microbiol* 74:4737–4745
15. Gibson GR, Cummings JH, Macfarlane GT et al (1990) Alternative pathways for hydrogen disposal during fermentation in the human colon. *Gut* 31:679–683
16. Dabard J, Bridonneau C, Phillippe C et al (2001) Ruminococcin A, a new lantibiotic produced by a *Ruminococcus gnavus* strain isolated from human feces. *Appl Environ Microbiol* 67:4111–4118
17. Santagati M, Scillato M, Patanè F et al (2012) Bacteriocin-producing oral streptococci and inhibition of respiratory pathogens. *FEMS Immunol Med Microbiol* 65:23–31
18. Gillor O, Etzion A, Riley MA (2008) The dual role of bacteriocins as anti- and probiotics. *Appl Microbiol Biotechnol* 81:591–606
19. Davey ME, O’toole GA (2000) Microbial biofilms: from ecology to molecular genetics. *Microbiol Mol Biol Rev* 64:847–867
20. Marsh PD, Moter A, Devine DA (2011) Dental plaque biofilms: communities, conflict and control. *Periodontology* 2000 2000(55): 16–35
21. Boles BR, Thoendel M, Singh PK (2004) Self-generated diversity produces “insurance effects” in biofilm communities. *Proc Natl Acad Sci U S A* 101:16630–16635
22. Stewart PS, Franklin MJ (2008) Physiological heterogeneity in biofilms. *Nat Rev Microbiol* 6:199–210
23. Frost LS, Leplae R, Summers AO et al (2005) Mobile genetic elements: the agents of open source evolution. *Nat Rev Microbiol* 3: 722–732
24. Gogarten JP, Townsend JP (2005) Horizontal gene transfer, genome innovation and evolution. *Nat Rev Microbiol* 3:679–687
25. Norman A, Hansen LH, Sørensen SJ (2009) Conjugative plasmids: vessels of the communal gene pool. *Philos Trans R Soc Lond B Biol Sci* 364:2275–2289
26. Jones BV, Marchesi JR (2007) Accessing the mobile metagenome of the human gut microbiota. *Mol Biosyst* 3:749–758
27. Dobrindt U, Hochhut B, Hentschel U et al (2004) Genomic islands in pathogenic and environmental microorganisms. *Nat Rev Microbiol* 2:414–424
28. Baquero F (2004) From pieces to patterns: evolutionary engineering in bacterial pathogens. *Nat Rev Microbiol* 2:510–518
29. Salyers AA (1993) Gene transfer in the mammalian intestinal tract. *Curr Opin Biotechnol* 4:294–298

30. Reid G, Younes JA, Van der Mei HC et al (2010) Microbiota restoration: natural and supplemented recovery of human microbial communities. *Nat Rev Microbiol* 9:27–38
31. Koenig JE, Spor A, Scalfone N et al (2010) Succession of microbial consortia in the developing infant gut microbiome. *Proc Natl Acad Sci U S A* 108(Suppl 1):4578–4585
32. Van den Abbeele P, Van de Wiele T, Verstraete W et al (2011) The host selects mucosal and luminal associations of coevolved gut microorganisms: a novel concept. *FEMS Microbiol Rev* 35:681–704
33. Giraud A, Arous S, De Paep M et al (2008) Dissecting the genetic components of adaptation of *Escherichia coli* to the mouse gut. *PLoS Genet* 4:e2
34. Gill SR, Pop M, Deboy RT et al (2006) Metagenomic analysis of the human distal gut microbiome. *Science* 312:1355–1359
35. Bäckhed F, Ley RE, Sonnenburg JL et al (2005) Host-bacterial mutualism in the human intestine. *Science* 307:1915–1920
36. Guarner F, Malagelada J-R (2003) Gut flora in health and disease. *Lancet* 361:512–519
37. Stappenbeck TS, Hooper LV, Gordon JI (2002) Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. *Proc Natl Acad Sci U S A* 99:15451–15455
38. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F et al (2004) Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* 118:229–241
39. Hooper LV (2004) Bacterial contributions to mammalian gut development. *Trends Microbiol* 12:129–134
40. Pryde SE, Duncan SH, Hold GL et al (2002) The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett* 217:133–139
41. Round JL, Mazmanian SK (2010) Inducible Foxp3⁺ regulatory T-cell development by a commensal bacterium of the intestinal microbiota. *Proc Natl Acad Sci U S A* 107:12204–12209
42. Wu GD, Chen J, Hoffmann C et al (2011) Linking long-term dietary patterns with gut microbial enterotypes. *Science* 334:105–108
43. Serino M, Luche E, Gres S et al (2012) Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. *Gut* 61:543–553
44. Honda K, Littman DR (2011) The Microbiome in Infectious Disease and Inflammation. *Annu Rev Immunol* 30:759–795
45. Ley RE, Bäckhed F, Turnbaugh P et al (2005) Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A* 102:11070–11075
46. Turnbaugh PJ, Bäckhed F, Fulton L et al (2008) Diet-induced obesity is linked to marked but reversible alterations in the mouse distal gut microbiome. *Cell Host Microbe* 3:213–223
47. Murphy EF, Cotter PD, Healy S et al (2010) Composition and energy harvesting capacity of the gut microbiota: relationship to diet, obesity and time in mouse models. *Gut* 59:1635–1642
48. Cerf-Bensussan N, Gaboriau-Routhiau V (2010) The immune system and the gut microbiota: friends or foes? *Nat Rev Immunol* 10:735–744
49. Wen L, Ley RE, Volchkov PY et al (2008) Innate immunity and intestinal microbiota in the development of Type 1 diabetes. *Nature* 455:1109–1113
50. Lee YK, Menezes JS, Umesaki Y et al (2010) Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. *Proc Natl Acad Sci U S A* 108(Suppl 1):4615–4622
51. Abraham C, Cho JH (2009) Inflammatory bowel disease. *N Engl J Med* 361:2066–2078
52. Nell S, Suerbaum S, Josenhans C (2010) The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models. *Nat Rev Microbiol* 8:564–577
53. Sokol H, Seksik P, Furet JP et al (2009) Low counts of faecalibacterium prausnitzii in colitis microbiota. *Inflamm Bowel Dis* 15:1183–1189
54. Manichanh C, Rigottier-Gois L, Bonnaud E et al (2006) Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. *Gut* 55:205–211
55. He T, Venema K, Priebe MG et al (2008) The role of colonic metabolism in lactose intolerance. *Eur J Clin Invest* 38:541–547
56. He T, Priebe MG, Harmsen HJM et al (2006) Colonic fermentation may play a role in lactose intolerance in humans. *J Nutr* 136:58
57. Tehrani AB, Nezami BG, Gewirtz A et al (2012) Obesity and its associated disease: a role for microbiota? *Neurogastroenterol Motil* 24:305–311
58. Everard A, Lazarevic V, Derrien M et al (2011) Responses of gut microbiota and glucose and lipid metabolism to prebiotics in genetic obese and diet-induced leptin-resistant mice. *Diabetes* 60:2775–2786
59. Giongo A, Gano KA, Crabb DB et al (2010) Toward defining the autoimmune microbiome for type 1 diabetes. *ISME J* 5:82–91

60. Wu H-J, Ivanov II, Darce J et al (2010) Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. *Immunity* 32:815–827
61. Lam V, Su J, Koprowski S et al (2012) Intestinal microbiota determine severity of myocardial infarction in rats. *FASEB J* 26(4): 1727–1735
62. Wardwell LH, Huttenhower C, Garrett WS (2011) Current concepts of the intestinal microbiota and the pathogenesis of infection. *Curr Infect Dis Rep* 13:28–34
63. Gori A, Tincati C, Rizzardini G et al (2008) Early impairment of gut function and gut flora supporting a role for alteration of gastro-intestinal mucosa in human immunodeficiency virus pathogenesis. *J Clin Microbiol* 46:757–758
64. Stecher B, Hardt W-D (2008) The role of microbiota in infectious disease. *Trends Microbiol* 16:107–114
65. Walk ST, Young VB (2008) Emerging insights into antibiotic-associated diarrhea and *Clostridium difficile* infection through the lens of microbial ecology. *Interdiscip Perspect Infect Dis* 2008:125081
66. Vrieze A, Holleman F, Zoetendal EG et al (2010) The environment within: how gut microbiota may influence metabolism and body composition. *Diabetologia* 53:606–613
67. Hou JK, Abraham B, El-Serag H (2011) Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. *Am J Gastroenterol* 106: 563–573
68. Fava F, Lovegrove JA, Gitau R et al (2006) The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. *Curr Med Chem* 13:3005–3021
69. Wang Z, Klipfell E, Bennett BJ et al (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 472:57–63
70. Dobkin JF, Saha JR, Butler VP et al (1983) Digoxin-inactivating bacteria: identification in human gut flora. *Science* 220:325–327
71. Clayton TA, Baker D, Lindon JC et al (2009) Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. *Proc Natl Acad Sci U S A* 106:14728–14733
72. Wallace BD, Wang H, Lane KT et al (2010) Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science* 330:831–835
73. Marsh PD (1994) Microbial ecology of dental plaque and its significance in health and disease. *Adv Dent Res* 8:263–271
74. Azarpazhooh A, Leake JL (2006) Systematic review of the association between respiratory diseases and oral health. *J Periodontol* 77:1465–1482
75. Ford PJ, Gemmell E, Timms P et al (2007) Anti-P. gingivalis response correlates with atherosclerosis. *J Dent Res* 86:35–40
76. Li L, Messas E, Batista EL et al (2002) Porphyromonas gingivalis infection accelerates the progression of atherosclerosis in a heterozygous apolipoprotein e-deficient murine model. *Circulation* 105:861–867
77. Koren O, Spor A, Felin J et al (2010) Human oral, gut, and plaque microbiota in patients with atherosclerosis. *Proc Natl Acad Sci U S A* 108(Suppl 1):4592–4598
78. Haug MC, Tanner SA, Lacroix C et al (2011) Monitoring horizontal antibiotic resistance gene transfer in a colonic fermentation model. *FEMS Microbiol Ecol* 78:210–219
79. Nelson KE, Weinstock GM, Highlander SK et al (2010) A catalog of reference genomes from the human microbiome. *Science* 328: 994–999
80. Methe BA, Nelson KE, Pop M et al (2012) A framework for human microbiome research. *Nature* 486:215–221
81. Park J, Kerner A, Burns MA et al (2011) Microdroplet-enabled highly parallel cocultivation of microbial communities. *PLoS One* 6:e17019
82. Bollmann A, Lewis K, Epstein SS (2007) Incubation of environmental samples in a diffusion chamber increases the diversity of recovered isolates. *Appl Environ Microbiol* 73:6386–6390
83. Thomas CM, Nielsen KM (2005) Mechanisms of, and barriers to, horizontal gene transfer between bacteria. *Nat Rev Microbiol* 3: 711–721
84. Lorenz MG, Wackernagel W (1994) Bacterial gene transfer by natural genetic transformation in the environment. *Microbiol Rev* 58:563–602
85. Wirth R, Friesenegger A, Fiedler S (1989) Transformation of various species of gram-negative bacteria belonging to 11 different genera by electroporation. *Mol Gen Genet* 216:175–177
86. Sanford JC, Smith FD, Russell JA (1993) Optimizing the biolistic process for different biological applications. *Methods Enzymol* 217:483–509
87. Wyber JA, Andrews J, D'Emanuele A (1997) The use of sonication for the efficient delivery of plasmid DNA into cells. *Pharm Res* 14: 750–756

88. Swords WE (2003) Chemical transformation of *E. coli*. *Methods Mol Biol* 235:49–53
89. Thomson AM, Flint HJ (1989) Electroporation induced transformation of *Bacteroides ruminalicola* and *Bacteroides uniformis* by plasmid DNA. *FEMS Microbiol Lett* 52:101–104
90. Calvin NM, Hanawalt PC (1988) High-efficiency transformation of bacterial cells by electroporation. *J Bacteriol* 170:2796–2801
91. Goodman AL, McNulty NP, Zhao Y et al (2009) Identifying genetic determinants needed to establish a human gut symbiont in its habitat. *Cell Host Microbe* 6:279–289
92. Kleckner N (1981) Transposable elements in prokaryotes. *Annu Rev Genet* 15:341–404
93. Goodman AL, Wu M, Gordon JI (2011) Identifying microbial fitness determinants by insertion sequencing using genome-wide transposon mutant libraries. *Nat Protoc* 6:1969–1980
94. van Opijnen T, Bodi KL, Camilli A (2009) Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction studies in microorganisms. *Nat Methods* 6:767–772
95. Gawronski JD, Wong SM, Giannoukos G et al (2009) Tracking insertion mutants within libraries by deep sequencing and a genome-wide screen for *Haemophilus* genes required in the lung. *Proc Natl Acad Sci U S A* 106:16422–16427
96. Langridge GC, Phan MD, Turner DJ et al (2009) Simultaneous assay of every *Salmonella* Typhi gene using one million transposon mutants. *Genome Res* 19:2308–2316
97. Sommer MO, Dantas G, Church GM (2009) Functional characterization of the antibiotic resistance reservoir in the human microflora. *Science* 325:1128–1131
98. Warner JR, Reeder PJ, Karimpour-Fard A et al (2010) Rapid profiling of a microbial genome using mixtures of barcoded oligonucleotides. *Nat Biotechnol* 28:856–862
99. Sandoval NR, Kim JY, Glebes TY et al (2012) Strategy for directing combinatorial genome engineering in *Escherichia coli*. *Proc Natl Acad Sci U S A* 109:10540–10545
100. Wang HH, Isaacs FJ, Carr PA et al (2009) Programming cells by multiplex genome engineering and accelerated evolution. *Nature* 460:894–898
101. Wang HH, Church GM (2011) Multiplexed genome engineering and genotyping methods applications for synthetic biology and metabolic engineering. *Methods Enzymol* 498:409–426
102. Wang HH, Kim H, Cong L et al (2012) Genome-scale promoter engineering by coselection MAGE. *Nat Methods* 9:591–593
103. Carr PA, Wang HH, Sterling B et al (2012) Enhanced multiplex genome engineering through co-operative oligonucleotide co-selection. *Nucleic Acids Res* 40:e132
104. Sharan SK, Thomason LC, Kuznetsov SG et al (2009) Recombineering: a homologous recombination-based method of genetic engineering. *Nat Protoc* 4:206–223
105. Isaacs FJ, Carr PA, Wang HH et al (2011) Precise manipulation of chromosomes in vivo enables genome-wide codon replacement. *Science* 333:348–353
106. Swingle B, Markel E, Costantino N et al (2010) Oligonucleotide recombination in Gram-negative bacteria. *Mol Microbiol* 75:138–148
107. van Pijkeren J-P, Britton RA (2012) High efficiency recombineering in lactic acid bacteria. *Nucleic Acids Res* 40:e76
108. Swingle B, Bao Z, Markel E et al (2010) Recombineering using RecTE from *Pseudomonas syringae*. *Appl Environ Microbiol* 76:4960–4968
109. van Kessel JC, Hatfull GF (2007) Recombineering in *Mycobacterium tuberculosis*. *Nat Methods* 4:147–152
110. Sonnenburg JL, Angenent LT, Gordon JI (2004) Getting a grip on things: how do communities of bacterial symbionts become established in our intestine? *Nat Immunol* 5:569–573
111. Faith JJ, McNulty NP, Rey FE et al (2011) Predicting a human gut microbiota's response to diet in gnotobiotic mice. *Science* 333:101–104
112. Hosoda K, Suzuki S, Yamauchi Y et al (2011) Cooperative adaptation to establishment of a synthetic bacterial mutualism. *PLoS One* 6:e17105
113. Shou W, Ram S, Vilar JM (2007) Synthetic cooperation in engineered yeast populations. *Proc Natl Acad Sci U S A* 104:1877–1882
114. Wintermute EH, Silver PA (2010) Emergent cooperation in microbial metabolism. *Mol Syst Biol* 6:407
115. Mee JM, Wang HH (2012) Engineering ecosystems and synthetic ecologies. *Mol Biosyst* 8:2470–2483
116. Saeidi N, Wong CK, Lo TM et al (2011) Engineering microbes to sense and eradicate *Pseudomonas aeruginosa*, a human pathogen. *Mol Syst Biol* 7:521
117. Duan F, March JC (2010) Engineered bacterial communication prevents *Vibrio cholerae*

- virulence in an infant mouse model. *Proc Natl Acad Sci U S A* 107:11260–11264
118. Steidler L (2000) Treatment of murine colitis by lactococcus lactis secreting interleukin-10. *Science* 289:1352–1355
 119. Steidler L, Rottiers P, Coulie B (2009) Actobiotics as a novel method for cytokine delivery. *Ann N Y Acad Sci* 1182:135–145
 120. Duncan SH, Scott KP, Ramsay AG et al (2003) Effects of alternative dietary substrates on competition between human colonic bacteria in an anaerobic fermentor system. *Appl Environ Microbiol* 69:1136–1142
 121. Leitch ECM, Walker AW, Duncan SH et al (2007) Selective colonization of insoluble substrates by human faecal bacteria. *Environ Microbiol* 9:667–679
 122. Macfarlane GT, Hay S, Gibson GR (1989) Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system. *J Appl Bacteriol* 66:407–417
 123. Molly K, Woestyne M, Verstraete W (1993) Development of a 5-step multi-chamber reactor as a simulation of the human intestinal microbial ecosystem. *Appl Microbiol Biotechnol* 39:254–258
 124. Possemiers S, Verthé K, Uyttendaele S et al (2004) PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem. *FEMS Microbiol Ecol* 49:495–507
 125. Pratten J (2007) Growing oral biofilms in a constant depth film fermentor (CDFS). *Curr Protoc Microbiol* Chapter 1, Unit 1B.5
 126. Ready D (2002) Composition and antibiotic resistance profile of microcosm dental plaques before and after exposure to tetracycline. *J Antimicrob Chemother* 49:769–775
 127. Roberts AP, Pratten J, Wilson M et al (1999) Transfer of a conjugative transposon, Tn5397 in a model oral biofilm. *FEMS Microbiol Lett* 177:63–66
 128. Roberts AP, Cheah G, Ready D et al (2001) Transfer of Tn916-like elements in microcosm dental plaques. *Antimicrob Agents Chemother* 45:2943–2946
 129. Kim HJ, Huh D, Hamilton G et al (2012) Human Gut-on-a-Chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. *Lab Chip* 12:2165–2174
 130. Trosvik P, Rudi K, Stråtkevren KO et al (2010) Web of ecological interactions in an experimental gut microbiota. *Environ Microbiol* 12:2677–2687
 131. Foster JS, Kolenbrander PE (2004) Development of a multispecies oral bacterial community in a saliva-conditioned flow cell. *Appl Environ Microbiol* 70:4340
 132. Doucet-Populaire F, Trieu-Cuot P, Dosbaa I et al (1991) Inducible transfer of conjugative transposon Tn1545 from *Enterococcus faecalis* to *Listeria monocytogenes* in the digestive tracts of gnotobiotic mice. *Antimicrob Agents Chemother* 35:185–187
 133. Launay A, Ballard SA, Johnson PDR et al (2006) Transfer of vancomycin resistance transposon Tn1549 from *Clostridium symbiosum* to *Enterococcus* spp. in the gut of gnotobiotic mice. *Antimicrob Agents Chemother* 50:1054
 134. Turnbaugh PJ, Ridaura VK, Faith JJ et al (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. *Sci Transl Med* 1:6ra14
 135. Rawls JF, Mahowald MA, Ley RE et al (2006) Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. *Cell* 127:423–433
 136. Sellon RK, Tonkonogy S, Schultz M et al (1998) Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. *Infect Immun* 66:5224–5231
 137. Lalla E, Lamster IB, Hofmann MA et al (2003) Oral infection with a periodontal pathogen accelerates early atherosclerosis in apolipoprotein E-null mice. *Arterioscler Thromb Vasc Biol* 23:1405–1411
 138. Caricilli AM, Picardi PK, de Abreu LL et al (2011) Gut microbiota is a key modulator of insulin resistance in TLR 2 knockout mice. *PLoS Biol* 9:e1001212
 139. Vijay-Kumar M, Aitken JD, Carvalho FA et al (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. *Science* 328:228–231
 140. Hapfelmeier S, Hardt W-D (2005) A mouse model for *S. typhimurium*-induced enterocolitis. *Trends Microbiol* 13:497–503
 141. Deng W, Vallance BA, Li Y et al (2003) *Citrobacter rodentium* translocated intimin receptor (Tir) is an essential virulence factor needed for actin condensation, intestinal colonization and colonic hyperplasia in mice. *Mol Microbiol* 48:95–115
 142. Newman JV, Zabel BA, Jha SS et al (1999) *Citrobacter rodentium* espB is necessary for signal transduction and for infection of laboratory mice. *Infect Immun* 67:6019–6025
 143. Alex P, Zachos NC, Nguyen T et al (2009) Distinct cytokine patterns identified from

- multiplex profiles of murine DSS and TNBS-induced colitis. *Inflamm Bowel Dis* 15:341–352
144. Oz HS, Puleo DA (2011) Animal models for periodontal disease. *J Biomed Biotechnol* 2011:1–8
 145. Naglik JR, Fidel PL, Odds FC (2008) Animal models of mucosal *Candida* infection. *FEMS Microbiol Lett* 283:129–139
 146. McBride BC, van der Hoeven JS (1981) Role of interbacterial adherence in colonization of the oral cavities of gnotobiotic rats infected with *Streptococcus mutans* and *Veillonella alcalescens*. *Infect Immun* 33:467–472
 147. Ma M, Rey FE, Seedorf H et al (2009) Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. *Proc Natl Acad Sci U S A* 106:5859–5864
 148. Sonnenburg JL, Chen CTL, Gordon JI (2006) Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. *PLoS Biol* 4:e413
 149. Lewis NE, Nagarajan H, Palsson BO (2012) Constraining the metabolic genotype-phenotype relationship using a phylogeny of in silico methods. *Nat Rev Microbiol* 10:291–305
 150. Zomorodi AR, Maranas CD (2012) OptCom: a multi-level optimization framework for the metabolic modeling and analysis of microbial communities. *PLoS Comput Biol* 8:e1002363
 151. Mahadevan R, Edwards JS, Doyle FJ 3rd (2002) Dynamic flux balance analysis of diauxic growth in *Escherichia coli*. *Biophys J* 83:1331–1340
 152. Greenblum S, Turnbaugh PJ, Borenstein E (2012) Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. *Proc Natl Acad Sci U S A* 109:594–599
 153. Zhuang K, Izallalen M, Mouser P et al (2011) Genome-scale dynamic modeling of the competition between *Rhodospirillum rubrum* and *Geobacter* in anoxic subsurface environments. *ISME J* 5:305–316
 154. Taffs R, Aston JE, Briley K et al (2009) In silico approaches to study mass and energy flows in microbial consortia: a syntrophic case study. *BMC Syst Biol* 3:114
 155. Turnbaugh PJ, Hamady M, Yatsunenkov T et al (2009) A core gut microbiome in obese and lean twins. *Nature* 457:480–484
 156. Rohlke F, Surawicz CM, Stollman N (2010) Fecal flora reconstitution for recurrent *Clostridium difficile* infection: results and methodology. *J Clin Gastroenterol* 44:567–570
 157. Miele E, Pascarella F, Giannetti E et al (2009) Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *Am J Gastroenterol* 104:437–443
 158. Gionchetti P, Rizzello F, Helwig U et al (2003) Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. *Gastroenterology* 124:1202–1209
 159. Mimura T, Rizzello F, Helwig U et al (2004) Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. *Gut* 53:108–114
 160. Culligan EP, Hill C, Sleator RD (2009) Probiotics and gastrointestinal disease: successes, problems and future prospects. *Gut Pathogens* 1:19
 161. Sartor RB (2004) Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. *Gastroenterology* 126:1620–1633
 162. Cronin M, Morrissey D, Rajendran S et al (2010) Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. *Mol Ther* 18:1397–1407
 163. Fu G-F, Li X, Hou Y-Y et al (2005) Bifidobacterium longum as an oral delivery system of endostatin for gene therapy on solid liver cancer. *Cancer Gene Ther* 12:133–140
 164. Li X, Fu G-F, Fan Y-R et al (2003) Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. *Cancer Gene Ther* 10:105–111
 165. Duan F, Curtis KL, March JC (2008) Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes. *Appl Environ Microbiol* 74:7437–7438
 166. Rao S, Hu S, McHugh L et al (2005) Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. *Proc Natl Acad Sci U S A* 102:11993–11998
 167. Braat H, Rottiers P, Hommes DW et al (2006) A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. *Clin Gastroenterol Hepatol* 4:754–759
 168. Degnan FH (2008) The US Food and Drug Administration and probiotics: regulatory categorization. *Clin Infect Dis* 46(Suppl 2):S133–S136, discussion S144–S151

169. Hong P-Y, Lee BW, Aw M et al (2010) Comparative analysis of fecal microbiota in infants with and without eczema. *PLoS One* 5:e9964
170. Saulnier DM, Riehle K, Mistretta T-A et al (2011) Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. *Gastroenterology* 141:1782–1791
171. Claesson MJ, Cusack S, O’Sullivan O et al (2011) Composition, variability, and temporal stability of the intestinal microbiota of the elderly. *Proc Natl Acad Sci U S A* 108(Suppl):4586–4591
172. Yatsunenko T, Rey FE, Manary MJ et al (2012) Human gut microbiome viewed across age and geography. *Nature* 486:222–227
173. Spor A, Koren O, Ley R (2011) Unravelling the effects of the environment and host genotype on the gut microbiome. *Nat Rev Microbiol* 9:279–290
174. De Filippo C, Cavalieri D, Di Paola M et al (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci U S A* 107:14691–14696
175. Peterson DA, Frank DN, Pace NR et al (2008) Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. *Cell Host Microbe* 3:417–427
176. Larsen N, Vogensen FK, van den Berg FWJ et al (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS One* 5:e9085
177. Kong HH, Oh J, Deming C et al (2012) Temporal shifts in the skin microbiome associated with atopic dermatitis disease flares and treatment. *Genome Res* 22(5):850–859
178. Gao Z, C-h T, Pei Z et al (2007) Molecular analysis of human forearm superficial skin bacterial biota. *Proc Natl Acad Sci U S A* 104:2927–2932
179. Keijser BJB, Zaura E, Huse SM et al (2008) Pyrosequencing analysis of the Oral Microflora of healthy adults. *J Dent Res* 87:1016–1020
180. Yang F, Zeng X, Ning K et al (2012) Saliva microbiomes distinguish caries-active from healthy human populations. *ISME J* 6:1–10
181. Phillips-Jones MK (1995) Introduction of recombinant DNA into *Clostridium* spp. *Methods Mol Biol* 47:227–235
182. Bouillaut L, McBride SM, Sorg JA (2011) Genetic manipulation of *Clostridium difficile*. *Curr Protoc Microbiol* Chapter 9, Unit 9A.2
183. Jennert KC, Tardif C, Young DI et al (2000) Gene transfer to *Clostridium cellulolyticum* ATCC 35319. *Microbiology* 146(Pt 12):3071–3080
184. Young DI, Evans VJ, Jefferies JR et al (1999) Genetic methods in clostridia. *Method Microbiol* 29:191–207
185. Cocconcetti PS, Ferrari E, Rossi F et al (1992) Plasmid transformation of *Ruminococcus albus* by means of high-voltage electroporation. *FEMS Microbiol Lett* 73:203–207
186. Damelin LH, Mavri-Damelin D, Klaenhammer TR et al (2010) Plasmid transduction using bacteriophage Phi(adh) for expression of CC chemokines by *Lactobacillus gasseri* ADH. *Appl Environ Microbiol* 76:3878–3885
187. Lizier M, Sarra PG, Cauda R et al (2010) Comparison of expression vectors in *Lactobacillus reuteri* strains. *FEMS Microbiol Lett* 308:8–15
188. Ljungh A, Wadström T (eds) (2009) *Lactobacillus molecular biology: from genomics to probiotics*. Caister Academic Press, Norfolk, UK
189. Sørvig E, Mathiesen G, Naterstad K et al (2005) High-level, inducible gene expression in *Lactobacillus sakei* and *Lactobacillus plantarum* using versatile expression vectors. *Microbiology* 151:2439–2449
190. Thompson K, Collins MA (1996) Improvement in electroporation efficiency for *Lactobacillus plantarum* by the inclusion of high concentrations of glycine in the growth medium. *J Microbiol Methods* 26:73–79
191. Shepard BD, Gilmore MS (1995) Electroporation and efficient transformation of *Enterococcus faecalis* grown in high concentrations of glycine. *Methods Mol Biol* 47:217–226
192. Holo H, Nes IF (1995) Transformation of *Lactococcus* by electroporation. *Methods Mol Biol* 47:195–199
193. Biswas I, Jha JK, Fromm N (2008) Shuttle expression plasmids for genetic studies in *Streptococcus mutans*. *Microbiology* 154: 2275–2282
194. McLaughlin RE, Ferretti JJ (1995) Electrotransformation of *Streptococci*. *Methods Mol Biol* 47:185–193
195. Lee JC (1995) Electrotransformation of *Staphylococci*. *Methods Mol Biol* 47: 209–216
196. Alexander JE, Andrew PW, Jones D et al (1990) Development of an optimized system for electroporation of *Listeria* species. *Lett Appl Microbiol* 10:179–181
197. Kuramitsu HK, Chi B, Ikegami A (2005) Genetic manipulation of *Treponema denticola*. *Curr Protoc Microbiol* Chapter 12, Unit 12B.12

198. Hyde JA, Weening EH, Skare JT (2011) Genetic transformation of *Borrelia burgdorferi*. *Curr Protoc Microbiol*, Chapter 12, 1–17
199. Rosa P, Stevenson B, Tilly K (1999) Genetic methods in *Borrelia* and other spirochaetes. *Method Microbiol* 29:209–227
200. Mayo B, van Sinderen D (2010) *Bifidobacteria: genomics and molecular aspects*. Caister Academic Press, Norfolk, UK
201. Yeung MK, Kozelsky CS (1994) Transformation of *Actinomyces* spp. by a gram-negative broad-host-range plasmid. *J Bacteriol* 176:4173–4176
202. Miles R, Nicholas R (eds) (1998) *Mycoplasma protocols*, vol 104, *Methods Mol Biol*. Humana Press, Totowa, NJ
203. Sasseti CM, Boyd DH, Rubin EJ (2001) Comprehensive identification of conditionally essential genes in mycobacteria. *Proc Natl Acad Sci U S A* 98:12712–12717
204. Luijk NV, Stierli MP, Schwenninger SM (2002) Genetics and molecular biology of propionibacteria. *Lait* 82:45–57
205. Binet R, Maurelli AT (2009) Transformation and isolation of allelic exchange mutants of *Chlamydia psittaci* using recombinant DNA introduced by electroporation. *Proc Natl Acad Sci U S A* 106:292–297
206. Bélanger M, Rodrigues P, Progulsk-Fox A (2007) Genetic manipulation of *Porphyromonas gingivalis*. *Curr Protoc Microbiol* Chapter 13, Unit 13C.12
207. Flint HJ, Martin JC, Thomson AM (2000) *Prevotella bryantii*, *P. ruminicola* and bacteroides strains. In: Eynard N, Teissié J (eds) *Electrotransformation of bacteria*. Springer, Heidelberg, pp 140–149
208. Nikolich MP, Salyers AA, Shoemaker NB (1994) Method and materials for introducing dna into *Prevotella ruminicola*. US Patent 5322784, Jun 21, 1994
209. Bacic MK, Smith CJ (2008) Laboratory maintenance and cultivation of bacteroides species. *Curr Protoc Microbiol* Chapter 13, Unit 13C 11
210. Salyers AA, Shoemaker N, Cooper A et al (1999) Genetic methods for bacteroides species. *Method Microbiol* 29:229–249
211. Smith CJ (1995) Genetic transformation of *Bacteroides* spp. using electroporation. *Methods Mol Biol* 47:161–169
212. Kinder Haake S, Yoder S, Gerardo SH (2006) Efficient gene transfer and targeted mutagenesis in *Fusobacterium nucleatum*. *Plasmid* 55:27–38
213. Segal ED (1995) Electroporation of *Helicobacter pylori*. *Methods Mol Biol* 47:179–184
214. Taylor DE (1992) Genetics of campylobacter and helicobacter. *Annu Rev Microbiol* 46:35–64
215. Rachek LI, Hines A, Tucker AM et al (2000) Transformation of *Rickettsia prowazekii* to erythromycin resistance encoded by the *Escherichia coli* *ereB* gene. *J Bacteriol* 182:3289–3291
216. McQuiston JR, Schurig GG, Sriranganathan N et al (1995) Transformation of *Brucella* species with suicide and broad host-range plasmids. *Methods Mol Biol* 47:143–148
217. Scarlato V, Ricci S, Rappuoli R et al (1996) Genetic manipulation of *Bordetella*. In: Adolph KW (ed) *Microbial genome methods*. CRC Press, Boca Raton, FL, pp 247–262
218. Bogdan JA, Minetti CA, Blake MS (2002) A one-step method for genetic transformation of non-piliated *Neisseria meningitidis*. *J Microbiol Methods* 49:97–101
219. Genco CA, Knapp JS, Clark VL (1984) Conjugation of plasmids of *Neisseria gonorrhoeae* to other *Neisseria* species: potential reservoirs for the β -lactamase plasmid. *J Infect Dis* 150:397–401
220. O'Dwyer CA, Langford PR, Kroll JS (2005) A novel neisserial shuttle plasmid: a useful new tool for meningococcal research. *FEMS Microbiol Lett* 251:143–147
221. Dennis JJ, Sokol PA (1995) Electrotransformation of *Pseudomonas*. *Methods Mol Biol* 47:125–133